Gliknik
Gliknik Inc
Gliknik Inc. is a pioneering biopharmaceutical company that specializes in the development of innovative biologics aimed at treating cancer and autoimmune disorders. The company's unique approach to drug development sets it apart in the biotech industry, as it seeks to create more effective and accessible alternatives to existing treatments.
Products & Team
GL-2045
GL-2045 is a recombinant Fc fusion protein developed to emulate the therapeutic effects of intravenous immunoglobulin (IVIG), providing a potentially more effective option for treating various autoimmune diseases.
GL-2045 addresses the challenge of providing a more effective and accessible treatment alternative to IVIG, active in a $12 billion annual market for autoimmune diseases.
Limited effectiveness and accessibility of current autoimmune and cancer treatments